Exploring Indole-Dihydropyrimidinone Derivatives: Design, Synthesis, Biological Assessment, SAR Analysis, and Evaluation of Mode of Action in Experimental Visceral Leishmaniasis
{"title":"Exploring Indole-Dihydropyrimidinone Derivatives: Design, Synthesis, Biological Assessment, SAR Analysis, and Evaluation of Mode of Action in Experimental Visceral Leishmaniasis","authors":"Garvita Mishra, Arvind Kumar Jaiswal, Ajay Kishor Kushawaha, Abhishek Kumar, Hemlata Bhatt, Alisha Ansari, Amol Chhatrapati Bisen, Rupa Hansda, Sristi Agrawal, Payel Acharjee, Rajdeep Guha, Rabi Sankar Bhatta, Bidyut Purkait, Koneni V. Sashidhara","doi":"10.1016/j.ejmech.2025.117667","DOIUrl":null,"url":null,"abstract":"The emergence of drug resistance and the non-availability of vaccines encouraged us to identify novel chemical scaffolds as new anti-leishmanial agents. In doing so, a series of thirty-four indole-dihydropyrimidinone hybrid compounds were synthesized using the Biginelli multicomponent reaction. These synthesized compounds were tested against <em>L. donovani in vitro</em> and <em>in vivo</em> in experimental golden hamster model of visceral leishmaniasis. Compounds <strong>4f</strong> and <strong>4m</strong> were found to have promising anti-leishmanial properties against intracellular amastigotes (IC<sub>50</sub> <strong>4.54</strong> & <strong>5.05</strong> μM, respectively) with minimal cytotoxicity against J774.1 macrophage. <strong>4f</strong> and <strong>4m</strong> were tested <em>in vivo</em>, and only 4f effectively cleared the parasite burden (>65%) in infected golden hamsters. Mode of action studies discloses that <strong>4f</strong> induces oxidative stress-mediated mitochondrial dysfunction and impairment of ATP production and triggers apoptosis. SAR and PK studies revealed that compound <strong>4f</strong> (indole-dihydropyrimidinone hybrid) may be used as a lead for developing future chemotherapeutic options for VL.","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"108 1","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ejmech.2025.117667","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
The emergence of drug resistance and the non-availability of vaccines encouraged us to identify novel chemical scaffolds as new anti-leishmanial agents. In doing so, a series of thirty-four indole-dihydropyrimidinone hybrid compounds were synthesized using the Biginelli multicomponent reaction. These synthesized compounds were tested against L. donovani in vitro and in vivo in experimental golden hamster model of visceral leishmaniasis. Compounds 4f and 4m were found to have promising anti-leishmanial properties against intracellular amastigotes (IC504.54 & 5.05 μM, respectively) with minimal cytotoxicity against J774.1 macrophage. 4f and 4m were tested in vivo, and only 4f effectively cleared the parasite burden (>65%) in infected golden hamsters. Mode of action studies discloses that 4f induces oxidative stress-mediated mitochondrial dysfunction and impairment of ATP production and triggers apoptosis. SAR and PK studies revealed that compound 4f (indole-dihydropyrimidinone hybrid) may be used as a lead for developing future chemotherapeutic options for VL.
期刊介绍:
The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers.
A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.